NASDAQ OMX

XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions

Dela

IL-1a Neutralizing Antibody MABp1 Found to Block NETs' Ability to Increase Endothelial Activation and Thrombogenicity

AUSTIN, Texas, Nov. 14, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today a presentation of findings on the role of IL-1 alpha (IL-1a) associated with Neutrophil Extracellular Traps (NETs) in promoting endothelial activation and thrombogenicity. The oral presentation, entitled, "Neutrophil Extracellular Traps Increase Endothelial Activation and Thrombogenicity via IL-1a and NF-KB: Implications for Superficial Erosion", was given by researcher Thomas L. Mawson, Icahn School of Medicine at Mount Sinai, Sarnoff Fellow, Sarnoff Cardiovascular Research Foundation, at the American Heart Association Scientific Sessions on November 13 at 5:45 PM, PT. Dr. Eduardo Folco, scientist at the Cardiovascular Division of Brigham and Women's Hospital and Harvard Medical School, contributed equally to this study.

The findings resulted from an agreement between XBiotech, Brigham and Women's Hospital (BWH), and Massachusetts General Hospital to provide XBiotech's anti-IL-1a antibody, MABp1, to Dr. Peter Libby.  Dr. Libby, a cardiovascular medicine specialist at BWH and the Mallinckrodt Professor of Medicine at Harvard Medical School, was principal investigator of the research.

"I believe these data represent an exciting step forward in cardiovascular medicine," stated Dr. Libby. He further added, "They elucidate a novel mechanism that we believe can contribute to coronary thrombosis, a major cause of sudden cardiac death and acute myocardial infarction. We have demonstrated that MABp1, an anti-IL-1a antibody, can block induction of key molecules in vascular endothelial cells that can promote erosion-associated thrombosis."

Coronary artery thrombosis can be caused by either plaque rupture or plaque erosion1. Superficial plaque erosion causes up to one-third of all acute coronary syndromes2,[3]. Erosion-prone atheromatous plaques, rather than lesions with stable or rupture-prone characteristics, associate with neutrophil extracellular traps (NETs)4. The study performed at Dr. Libby's laboratory probed the influence of NETs on the endothelial cell (EC) functions related to erosion-associated thrombosis. These data show that exposure of human saphenous veins ECs (HSVECs) to NETs increase expression of adhesion molecules on the surface of endothelial cells such as VCAM-1 and ICAM-1, which may participate in atherogenesis.  In addition, pre-treatment of NETs with MABp1, an anti-IL-1a-neutralizing antibody, or IL-1R antagonist, but not with an anti-IL-1B-neutralizing antibody, blocked the initiation of VCAM-1, ICAM-1, and TF expression, each of which link to coronary thrombosis5. In conclusion, NETs increase thrombogenicity in vitro through a response mediated by IL-1a. These data point to an important role for MABp1 therapy in heart disease. It also may expand treatment opportunities for other inflammatory diseases in which NETs play a deleterious role, such as cancer as well as pulmonary, autoimmune, and gastrointestinal diseases.

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

1 Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. Circulation 2017;136:1155-1166.

2 Franck G, et al. Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice - Implications for Superficial Erosion. Circ Res 2017;121:31-42.

3 Libby P. Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all. Eur Heart J. 2017;38(11):801-803. doi: 10.1093/eurheartj/ehw599.

4 Quillard T et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. 2015 Jun 7;36(22):1394-404. doi: 10.1093/eurheartj/ehv044. Epub 2015 Mar 8.

5 Tousoulis D, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993-7.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Nitinat Provides Progress Report on Carscallen and Jasper Properties23.4.2018 22:38Pressmeddelande

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Nitinat Minerals Corp. (the "Company") (TSXV:NZZ) (Frankfurt:04U1) is pleased to announce that the work on its 100% owned Carscallen Property is underway and is going as planned. The Corporation will be providing details on an ongoing basis as the work progresses and details become available. The Corporations is also pleased to announce the initiation of a work program on its 100% owned Jasper Property which is located inland from the western shore of Vancouver Island, B.C., roughly 80 kilometers Northwest of Victoria, lying in the area of Nitinat Creek and Lake and is accessed by logging roads coming in from the North. The Jasper Property consists of the Jas 3 legacy mineral claim and eight unnamed cell mineral claims that together comprise nine contiguous claims that cover 3978 hectares. The Jasper Property is 100% owned and operated by the Company. The Highly Visible mineralized showings on the Jasper claims lie in a rugged forested area a

Atico Reports Consolidated Financial Results for 201723.4.2018 22:30Pressmeddelande

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX-V:ATY) (OTC:ATCMF) today announced its financial results for the year ended December 31, 2017, posting income from mining operations of $15.32 million and a net income of $4.04 million. Production for the year at Atico's El Roble mine totaled 20.6 million pounds ("lbs") of copper and 10,923 ounces ("oz") of gold in concentrates at a cash cost(1) of $1.45 per payable pound of copper produced(2). Fernando E. Ganoza, CEO and Director, commented, "We are pleased to report our strongest year to date both operationally and financially, as the Company concluded 2017 exceeding nearly all set objectives for the year. Operationally, we delivered above our higher end guidance while further increasing operational standards at El Roble. Financially, we have delivered a record year in most metrics while significantly s

Luxoft Develops 'Blockchain Adapter' for a Business Process Management Tool on Appian's Platform23.4.2018 21:58Pressmeddelande

Luxoft to unveil healthcare use case for blockchain adapter at Appian World in Miami, April 23-25 (Booth 16) Zug, SWITZERLAND and Reston, VA -- 24 April, 2018 - Luxoft Holding Inc. (NYSE:LXFT), a global IT service provider, today announces it has built a blockchain adapter for Appian's (NASDAQ:APPN) rapid application development platform. It is now available exclusively to businesses using Appian's Business Process Management (BPM) tool and will allow its users to integrate a blockchain network into their day-to-day business processes, creating a secure, digital environment that facilitates data sharing. "The launch of this adapter is about helping businesses realise the potential of blockchain by making it easier to use," said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. "Problems integrating blockchain into existing in-house systems are often the biggest obstacles to its adoption. Now, by integrating blockchain into a BPM, a business can leverage the benefits of

Mitratech Acquires ThinkSmart LLC to Create Industry-First, End-to-End Legal Operations Platform23.4.2018 17:00Pressmeddelande

Integration of ThinkSmart's agile workflow software into Mitratech's TeamConnect platform sets a new global standard for legal and compliance innovation and excellence LAS VEGAS, April 23, 2018 (GLOBE NEWSWIRE) -- Today, Mitratech a leading provider of legal and compliance software, announced the acquisition of ThinkSmart LLC, creating an end-to-end platform designed to transform legal operations into a center of innovation and excellence. With the addition of ThinkSmart and the ThinkSmart Automation Platform (TAP), Mitratech's TeamConnect platform can now bring people, processes and information together like never before, by leveraging TAP's easy-to-use workflow automation engine to extend TeamConnect's reach across the entire enterprise. In today's rapidly evolving legal landscape, there is a need for a truly evolutionary Enterprise Legal Management (ELM) platform. ELM systems have delivered on the operational efficiencies, centralized view of information, security and data integrity

Vricon unveils new solution at GEOINT 2018: Vricon Precision 3D Registration (P3DR)23.4.2018 16:20Pressmeddelande

Precise, accurate, georegistered GEOINT data for analytics and visualization-at a global scale McLean, Virginia, April 23, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that it is unveiling the next in a series of GEOINT solutions - Vricon Precision 3D Registration (P3DR) - at this year's GEOINT 2018 Symposiumin Tampa, Fla. Vricon P3DR is a software suite designed to automatically georegister imagery, regardless of collection platform, against the most accurate 3D geospatial foundation available, The Globe in 3D. P3DR can be implemented as a real-time processing workflow for imagery feeds without the need for GPS location, heading information, or ground control points. "While we've always been able to perform georegistration of individual data sets using our 3D models as an accurate foundation, Vricon P3DR takes this capability to a whole new level," said Magnus Brege, Vricon CEO. "Our users now have multiple options for where and when they can automatically georegister their

Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA23.4.2018 14:15Pressmeddelande

First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the Company's AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. "We are encouraged to have received the first gene therapy RMAT designation in MPS IIIA and look forward to further collaborating with the FDA to determine next steps in the development pathway for ABO-102," said Carsten Thiel, Ph.D., CEO of Abeona Therapeutics. "This action further reinforces the clinical significance in the data observed in the ongoing P

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum